// App-Quantinova.ai

1472 : Enzymatic depletion of adenosine by pegylated, engineered adenosine deaminase 2 (PEG-ADA2): A novel immunotherapeutic approach to treat solid tumors

Researchers

Presenter

  • Lin Wang

Principal Investigators

  • Jessica Cowell

  • Sanna Rosengren

  • Lei Huang

  • Xiaoming Li

  • Qiping Zhao

  • Jennifer Souratha

  • Mathieu Marella

  • Barbara Blouw

  • Keri Cannon

  • Chunmei Zhao

  • Kim Phan

  • Curtis Thompson

  • Michael Shepard

  • Christopher Thanos

Medical Centers

  • Halozyme Therapeutics, San Diego, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • 5'-nucleotidase

  • Adenosine deaminase RNA specific

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Adenosine

  • Adenosine Intravenous

  • Heparin

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved